NovoCure (NVCR) Other Operating Expenses (2014 - 2026)

NovoCure (NVCR) has reported Other Operating Expenses for 13 consecutive years, with $51.4 million the latest figure, recorded in Q2 2026.

• Quarterly Other Operating Expenses fell 7.85% year-over-year to $51.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $224.7 million (up 5.65% YoY) and the FY2025 annual result came in at $224.5 million, up 7.11% from the prior year.
• Other Operating Expenses declined to $51.4 million in Q2 2026 per NVCR's latest filing, from $58.3 million in the prior quarter.
• Over the last five years, Other Operating Expenses for NVCR reached as high as $60.9 million in Q4 2025 and fell as low as $37.9 million in Q1 2022.
• A 5-year average of $51.8 million and a median of $52.8 million in 2023 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2023 — Other Operating Expenses surged 35.07% — and 2026, when it slipped 7.85%.
• Year by year, Other Operating Expenses stood at $49.6 million in 2022, then gained by 11.71% to $55.4 million in 2023, then dropped by 7.63% to $51.2 million in 2024, then grew by 18.93% to $60.9 million in 2025, then fell by 15.53% to $51.4 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $51.4 million, $58.3 million, and $60.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.